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Abstract 
Background: Placental soluble fms-like tyrosine kinase-1 (sFlt-1) which is an antagonist of vascular endothelial 
growth factor and placental growth factor (PIGF), is considered as one of etiology factors cause endothelial damage 
in preeclampsia due to increase of sFlt-1 level that change vascular endothelial integrity. This study aims to analyze 
the difference of sFlt-1 and PlGF concentration in severe preeclampsia and normal pregnancy, and the correlation 
between both in occurrence of severe preeclampsia.
Method: This is case control study involving 18 subjects with severe preeclampsia and 19 subjects with normal preg-
nancy as controls who met inclusion and exclusion criteria. Concentration of sFlt-1 and PlGF are measured with ELISA. 
Statistical analysis is performed with Chi square test, Fisher’s exact test, T test, Mann–Whitney test, and Spearman’s 
rank correlation test.
Results: This study results in no significant difference in characteristics of gestational age, and parity in both study 
groups. Median concentration of sFlt-1 in severe preeclampsia is higher (20,524.75 pg/mL) compared with normal 
pregnancy (6820.4 pg/mL). Concentration of PlGF is lower in severe preeclampsia (47 pg/mL) compared with normal 
pregnancy (337 pg/mL). sFlt-1 concentration is higher in severe preeclampsia compared to normal pregnancy. PlGF 
concentration is lower in severe preeclampsia compared to normal pregnancy. Ratio of sFlt-1 and PlGF concentration 
is significantly correlated in both severe preeclampsia and normal pregnancy.
Conclusions: There is a significant negative correlation between the concentration of sFLt-1 and PlGF in normal 
pregnancy.
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Background
Gestational hypertension is one of some most common 
complications in pregnancy, labor, or postpartum which 
increases maternal and perinatal morbidity and mortality. 
Severe preeclampsia is a pregnancy-specific syndrome 
characterized by systolic blood pressure of ≥160 mmHg 
and diastolic blood pressure of ≥110 mmHg, with quali-
tative proteinuria of > +1 or 0.3  g/24  h. [1, 2] World 
Health Organization (WHO) in 2006, reported that 
almost 16 % of 3201 mortality caused by pregnancy was 
contributed by gestational hypertension [3]. Accord-
ing to data from National Center for Health Statistics in 
USA, gestational hypertension occurs in 150,000 women 
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or 3.7  % of all pregnancy [1]. National Vital Statistics 
recorded that incidence of preeclampsia increases by 
40  %. Survey done by SKDI in 2007 found that preec-
lampsia/eclampsia contributes to about 24  % mater-
nal mortality in Indonesia, makes it the second cause of 
maternal death in Indonesia. In Dr. Hasan Sadikin Hos-
pital, Bandung, preeclampsia was reported in 3.5 % cases 
and eclampsia in 2.8 % cases in 2006, while in 2008–2010 
preeclampsia was reported in 4.0–10.4 % and eclampsia 
in 2.3–4.3 % [4–10].
It has been hypothesized that the underlying mecha-
nism of preeclampsia involve genetic factor, immunologic 
factor, vascular disease, and conditions in which exces-
sive trophoblast were unable to invade spiral artery in the 
early phase of the first trimester. These cause spiral artery 
to dilate inadequately and disturbance in endothelial and 
muscular wall of blood vessel, leaves the blood vessel be 
smaller in diameter, leading to diminished perfusion and 
placental ischemia [11–13]. Placental ischemia causes 
elevated concentration of placental soluble FMS-like 
tyrosine kinase-1 (sFlt-1), which is an antiangiogenic fac-
tor produced by hypoxic placental cells [14–17]. sFlt-1 is 
believed as an etiologic factor of endothelial damage in 
preeclampsia. Elevated concentration of sFlt-1 will mod-
ify endothelial integrity of blood vessel, causing blood–
brain-barrier damage which lead to hepatic and brain 
edema, as well as hypertension and proteinuria encoun-
tered in preeclamptic patients. sFlt-1 can also be found in 
normal pregnancy after the 35th week [22]. sFlt-1 found 
in preeclamptic white people was about 4383 ± 657 pg/
ml, while being 1643 ± 940 pg/ml in normal pregnancy 
[18–20] Elevation of sFlt-1 concentration was found 
weeks before clinical onset of hypertension and proteinu-
ria [21–23].
Placental growth factor (PlGF), a type of vascular 
endothelial growth factor (VEGF), is a dimeric glyco-
protein amino-acid residue which is an important local 
mediator in angiogenesis. PlGF is produced by placenta 
(especially by cytotrophoblast, syncytiotrophoblast, 
and extra-filamentous trophoblast), endothel of human 
umbilical vein, and choriocarcinoma cells. Alteration of 
its circulating concentration may affect the balance of 
placental vessel angiogenesis, thus its presence is often 
associated with preeclampsia occurrence because it 
reflects abnormality in placental development [22, 24, 
25]. Studies have believed that PlGF alteration starting 
from 10 to 11th gestational week is a predisposing factor 
to preeclampsia in advanced pregnancy [23–25]. sFlt-1 is 
antagonistic to PlGF. Alteration of sFlt-1 and PlGF would 
cause imbalance of angiogenesis, followed by failure in 
trophoblastic invasion and physiological remodeling of 
spiral artery, thus placental hypoxia ensue [22, 23].
These raise a question whether disturbance in the bal-
ance of sFlt-1 and PlGF concentration was correlated 
with severity of clinical manifestation in patients. This 
study aims in comparing the concentration of sFlt-1 and 
PlGF in preeclamptic woman and normal pregnancy 
in the third trimester, and its correlation with patients’ 
clinical manifestations. The result is expected to be able 
in correlating clinical manifestation with theory of preec-
lampsia etiology, and to be used as a marker in detecting 
preeclampsia.
Results and discussion
Characteristic data, systolic and diastolic blood pressure, 
measurement of proteinuria, and blood to be measured 
for PlGF and sFlt-1 with ELISA method in Prodia labo-
ratory Bandung were collected from both study groups. 
Characteristics of parity, and gestational age were com-
pared for homogeneity.
As shown in Table 1, there is no significant difference 
in maternal parity (p =  0.105, p  >  0.05) and gestational 
age (p = 0.221, p > 0.05) between the two groups. Char-
acteristics of subjects are therefore homogenous. It has 
been documented that younger age, primigravida, and 
gestational age bring risk of preeclampsia as confound-
ing factor [1–3]. Incidence of preeclampsia is higher 
in young age and nulipara, while it also increases with 
advanced maternal age\due to increased risk of chronic 
hypertension, particularly in age older than 35 years old 
[3]. Characteristics of subjects in this study are homog-
enous in maternal age, gestational age, and parity.
Referring to the theory of preeclampsia and its patho-
physiology, which is imbalance of pro- and antian-
giogenic factor, correlation between sFlt-1 and PlGF 
concentration is important to be noted. There is a nega-
tive correlation between them: the higher is the sFlt-1, 
the lower is the PlGF [3].
Table  2 shows that concentration of sFlt-1 is signifi-
cantly higher in the group with severe preeclampsia 
(p < 0.001), while PlGF in that group is significantly lower 
than control (p < 0.001). Table 2 shows a rational correla-
tion between elevated concentration of sFlt-1 and reduced 
concentration of PlGF in the group with severe preec-
lampsia. Ratio of sFlt-1 and PlGF concentration is signifi-
cantly correlated in both severe preeclampsia and normal 
pregnancy (p < 0.001). The higher the sFlt-1, the lower is 
the PlGF, with the difference of severe preeclampsia group 
of almost 15 times greater than the normal pregnancy 
group. Referring to the theory of preeclampsia pathogen-
esis, hypoxic placenta will release sFlt-1, which is a free 
soluble, into maternal circulation and this will be followed 
by reduction of free PlGF. This change can be noticed in 
preeclamptic patient weeks before its onset [3].
Page 3 of 5Gurnadi et al. BMC Res Notes  (2015) 8:534 
It has been hypothesized that sFlt-1 concentration 
would continue to elevate as placental hypoxia advances, 
and this is associated with clinical manifestation of preec-
lampsia, which are elevated blood pressure and proteinu-
ria  [26]. In the group with severe preeclampsia, PlGF 
concentration continues to reduce, reflecting a negative 
correlation with sFlt-1. Elevation of circulating sFlt-1 
concentration would reduce PlGF concentration until 
endothelial dysfunction ensues. This condition can be 
noted a few weeks before preeclampsia, therefore can be 
used as a diagnostic tool of preeclampsia [3, 18, 19, 27]. 
When elevated sFlt-1 is found in a woman without clini-
cal manifestation of preeclampsia, the woman will have 
preeclampsia in the next few weeks, theoretically [19]. 
Parenteral administration of sFlt-1 on animals had been 
documented to elevate blood pressure, proteinuria, and 
glomerular endotheliosis, which are similar with clinical 
manifestations of preeclampsia. Preventing damage in 
glomerular endothelium can be achieved by reduction 
VEGF (VEGF-inhibitor administration) [3, 20].
Table  3 shows there is a negative correlation between 
elevated concentration of sFlt-1 and PlGF concentration. 
It is not significant in severe preeclampsia (r = −0.347), 
but very significant in normal pregnancy (r  = −0.508). 
With both are combined, there is a very significant corre-
lation in sFlt-1/PlGF ratio (r = 0.186). There is correlation 
between change of sFlt-1/PlGF concentration in severe 
preeclampsia and normal pregnancy, but it is not signifi-
cant (0 < r < 1). This proves that elevated sFlt-1 concen-
tration as antiangiogenic factor and reduction of PlGF 
as proangiogenic factor occur in pathogenesis of preec-
lampsia [28, 29, 31]. sFlt-1 concentration in preeclamptic 
women was found to be elevated, this leads to antagonis-
tic process to VEGF and PlGF. As mentioned above, PlGF 
is produced by placenta and its concentration elevates 
during pregnancy without preeclampsia [30].
Not significant correlation of sFlt-1/PlGF might be 
caused that etiology of preeclampsia is multifactorial. A 
theory has been explained in a study by Aggarwal et al. 
that preeclampsia is not only caused by sFlt-1 elevation 
and PlGF reduction, but also by endothelin-1 (ET-1), 
a potent peptide with vasoconstrictive effect, which is 
released by endothelium and muscles of blood vessel [3, 
17].
Further studies including variation in parity, gesta-
tional age, maternal age, and clinical manifestations to 
learn sFlt-1 and PlGF concentration according to parity, 
gestational age, and maternal age, and studies with larger 
number of samples, are encouraged.
Study limitation
In this study, samples used were small and it might not 
reflect the real findings.
Conclusion
Concentration of sFlt-1 in severe preeclampsia is higher 
than its concentration in normal pregnancy, while PlGF 
concentration in severe preeclampsia is lower than its 
Table 1 Characteristic of study subjects by parity and ges-
tational age
p value is analyzed with Chi square test, except for the maternal age (analyzed 
with t test) and parity (analyzed with Fisher’s exact test)*





 Primi 18 15 0.105*
 Multi 0 4
Gestational age 
(weeks)
 37 8 10 0.221
 38 6 2
 39 4 7
Mean (±SD) 37.8 (0.8) 32.4 (5.4)
Median 38 37
Range 37–39 37–39
Table 2 Comparison of  sFlt-1 and  PlGF concentration 
in severe preeclampsia and normal pregnancy
p value is analyzed with Mann–Whitney test; sFlt-1 is analyzed with t test
Characteristics Group p value
Preeclampsia (n = 18) Normal (n = 19)
sFlt-1 (pg/dl) <0.001
 Median 20,524.75 6820.4
 Range 1430.5–28,540.5 1657.6–18,859.6
PlGF (pg/dl)
 Median 47 337 <0.001
 Range 10–1361 54–1156
Table 3 Correlation of  sFlt-1/PlGF ratio in  severe preec-
lampsia and normal pregnancy
Analyzed with Mann–Whitney test
Characteristic Group r value
Preeclampsia (n = 18) Normal (n = 19)
sFlt-1/PlGF (pg/ml)
 Median 303.0 20.2 0.186
 Range 4.71–2646.57 2.49–238.73
 r value −0.347 −0.508
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concentration on normal pregnancy. Ratio of sFlt-1/PlGF 
is positively-correlated in normal pregnancy.
Concentration of sFlt-1 is negatively-correlated with 
normal pregnancy. Concentration of sFlt-1 is negatively-
correlated with proteinuria degree in severe preec-
lampsia. Ratio of sFlt-1/PlGF is positively-correlated 
with diastolic blood pressure and proteinuria in severe 
preeclampsia.
Methods
This is a case control study. Pregnant women with sin-
gleton living-intrauterine fetus with gestational age of 
≥37 weeks according to the last day of menstrual period 
and medical record presented to Dr. Hasan Sadikin hos-
pital, Cibabat hospital, and Astana Anyar hospital in 
January 2011 to June 2011 were included in this study. 
Those with normal blood pressure and negative proteinu-
ria were included in control group (normal pregnancy), 
while those who meet criteria of preeclampsia with posi-
tive proteinuria were included in the preeclampsia group. 
Fetal congenital malformations confirmed with USG, 
mother having infection or history of chronic diseases 
(renal, cardiac, hypertension, diabetes mellitus, hypo-
thyroidism, peptic ulcer, etc.), who smokes or drink alco-
hol, and pregnancy with fetal growth restriction, were 
excluded. Subjects were taken consecutively, consisted 
of 18 preeclamptic patients and 19 women with normal 
pregnancy as control group.
Patients with preeclampsia (18 samples) and normal 
pregnancies as controls (19 samples) were managed 
according to guidelines therapy of Obstetric and Gyne-
cology Faculty of Medicine Padjadjaran University Hasan 
Sadikin Hospital (FKUP/RSHS), Bandung, through some 
tests includes: (1) anamnesis; name, age, address, parity, 
first day of last haid, gestational age, previous hyperten-
sion history, and current pregnancy disease. (2) blood 
pressure was measured by using sphigmomanometer to 
patients who were treated lying on its left side for 15 min. 
(3) 6 ml blood sample was taken from peripheral blood 
before birth, centrifuge at 1600g 10′ 4  °C. Blood sample 
was withdrawn and then kept in −20 °C temperature. (4) 
Levels of sFlt-1 and PlGF were performed by high sensi-
tivity indirect sandwich enzyme-linked immunosorbent 
assay (ELISA) in Prodia laboratory in Jakarta afterwards.
Data analyzing was begun by performing normality 
test. Categorical data were analyzed with Chi square or 
Fisher’s exact test when the expected value was less than 
5. Normally-distributed data were compared with T test, 
while not-normally-distributed ones were analyzed with 
Mann–Whitney test. Ratio of proteins was analyzed with 
Spearman’s rank correlation test. Data analysis was per-
formed with SPSS for Windows version 15.0, with 85 % 
confidence interval and p value of <0.05.
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